Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non‐small‐cell lung cancer. (15th April 2015)

• Record Type: Journal Article
• Authors: Schneider, T.; Sevko, A.; Heussel, C. P.; Umansky, L.; Beckhove, P.; Dienemann, H.; Safi, S.; Utikal, J.; Hoffmann, H.; Umansky, V.
• Is Part Of: Clinical and experimental immunology. Volume 180:Number 3(2015:Jun.)
• Page Start: 467
• Page End: 474
• Publication Date: 2015-04-15
• Subjects: Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.12596
• Languages: English
• ISSNs: 0009-9104

Abstract

<abstract abstract-type="main"> <title>Summary</title> <p>In recent years, percutaneous radiofrequency ablation (RFA) has been developed as a new tool in the treatment of non‐small‐cell lung cancer (NSCLC) in non‐surgical patients. There is growing evidence that RFA‐mediated necrosis can modulate host immune responses. Here we analysed serum inflammatory factors as well as immunosuppressive cells in the peripheral blood to discover possible prognostic indicators. Peripheral blood and serum samples were collected before RFA and within 3 months after the treatment in a total of 12 patients. Inflammatory cytokines and growth factors were measured in serum by the Bio‐Plex assay. Myeloid‐derived suppressor cells (MDSCs) and regulatory T cells (T<sub>regs</sub>) were evaluated in the peripheral blood via flow cytometry. In patients developing local or lymphogenic tumour relapse (<italic>n</italic> = 4), we found an early significant increase in the concentration of tumour necrosis factor (TNF)‐α as well as chemokine (C‐C motif) ligand (CCL)‐2 and CCL‐4 compared to patients without relapse (<italic>n</italic> = 4) and healthy donors (<italic>n</italic> = 5). These changes were associated with an elevated activity of circulating MDSC indicated by an increased nitric oxide (NO) production in these cells. Elevated serum levels of TNF‐α, CCL‐2 and CCL‐4 associated with an increased NO production in circulating MDSCs might be an early indicator of the incomplete RFA and subsequently a potential tumour relapse in NSCLC.</p> </abstract>